On the heels of solid tumor data and with competitors surging, Poseida scraps autologous CAR-T in favor of allo

Poseida CEO Eric Ostertag was not shy about the prospects he sees for autologous CAR-T therapies in the age of off-the-shelf alternatives: They are “going the way of the dinosaur.” His company is officially starting that pivot. In its quarterly update, San Diego-based Poseida announced that it’s winding down the…

Click here to view original post